Pay in 4 interest-free payments of $5.74 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
Tremfya (guselkumab) Disease area(s): Immunology Manufacturer(s): Johnson & Johnson 2024 Sales (USD): $3.67 billion Why it sold so well: J&Js IL-23 inhibitor Tremfya experienced significant sales growth last year with $3.67 billion in total sales, an increase of 16.6% from 2023
People vary in sensitivities, other health conditions, and concurrent therapies
I'm like, yeah, that's not
Decoding GLP-1: A Guide for Friends and Family of Those On The Pen By Dave Knapp SURVODUTIDE Phase 3 Data: Why Weight Loss Isn't The Whole Story A new GLP-1 and glucagon agonist dropped data that was supposed to rival retatrutide, just without the GIP, and on the surface the results look solid
This supports the idea that the medicine does not damage the heart
Acknowledgements This project was supported by the National Natural Science Foundation of China (32001642)
US$ 24.19
US$ 21.30
US$ 27.75
US$ 27.87
US$ 26.93
US$ 25.75
US$ 21.72
US$ 24.97
